ArticleBJC reports2026
Therapeutic challenges of a renal collision tumour comprising clear cell renal cell carcinoma and metastatic breast carcinoma: a case report.
Article in BJC reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Collision tumours, defined by the coexistence of two histologically distinct neoplasms within a single organ, are rare and typically arise from different cell lineages. We report a unique case of a 64-year-old woman with a history of oestrogen receptor (ER)-positive, HER2-negative breast carcinoma who developed a renal mass later identified as a collision tumour comprising clear cell renal cell carcinoma (ccRCC) and metastatic breast carcinoma. Initial imaging and biopsy suggested ccRCC alone; however, post-nephrectomy histopathology revealed metastatic breast carcinoma foci within the ccRCC and renal sinus fat, confirmed by ER, GATA3, and mammaglobin positivity. This case highlights diagnostic challenges in distinguishing synchronous primaries from metastases, particularly where biopsy sampling may obscure dual pathology. Management required balancing treatment of localised ccRCC with systemic therapy for metastatic breast cancer. Multidisciplinary evaluation is essential to guide optimal care.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.